| Ytd | -19.60% | |
| 1y | -22.29% |
| Open | 9.29 | Prev Close | 9.24 | Low | 9.17 | High | 9.77 | Mkt Cap | 2.14B |
| Vol | 0.00 | Avg Vol | 2.59M | EPS | -1.42 | P/E | -6.87 | Forward P/E | -6.32 |
| Beta | 0.94 | Short Ratio | 8.75 | Inst. Own | 96.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 9.14 | 200-d Avg | 10.01 | 1yr Est | 27.09 |
BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o
Ocular Therapeutix (OCUL) is positioned for a potential 2027 launch of AXPAXLI, with a de-risked reg
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.35 per share versus the Zacks Consens
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.35) per share which beat the analy
Ocular's AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting wi
Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a New Drug Application for AXPAXL
BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o
BEDFORD, Mass. , July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular")
BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
Ocular Therapeutix, Inc. (NASDAQ:OCUL) stock is trading higher on Wednesday as the company prepares
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safet
Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o
BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”),
In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. K
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targetin
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting r
BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or
Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transc
U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also
(Editor’s note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the h
Companies Reporting Before The Bell • Ballard Power Systems (NASDAQ:BLDP) is estimated to report qu
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the compa
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss a
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 pe
Companies Reporting Before The Bell • Passage Bio (NASDAQ:PASG) is estimated to report earnings for
Monday saw 196 companies set new 52-week lows.
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quar
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings fo
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quar
On Friday, 431 companies hit new 52-week lows.